Incidence of Bleeding on Probing as an Indicator of Peri-Implant Disease Progression (BOP)

November 1, 2023 updated by: Andrea Ravida, University of Pittsburgh

Incidence of Bleeding on Probing as an Indicator of Peri-Implant Disease Progression: A Prospective Study

The primary goal of the present prospective cohort study is to evaluate the effect of varying incidences of BOP at implant sites across 15 months of maintenance visits on the probability of peri-implant disease progression. Over 15 months, participants will attend 6 visits where clinical measurements and maintenance care will be performed every 3 months.

Study Overview

Detailed Description

Screening/Baseline/Maintenance Visit 1 (V1) After participants have consented, their health history will be reviewed, and their vitals including blood pressure and heart rate will be recorded. A dental exam of the teeth and gums will be completed. During this exam, a UNC 15 periodontal probe will be used to perform the clinical assessments. Intraoral photographs will be taken. An x-ray of the implant(s) included in the study will be taken using a customized x-ray holder (created during Visit 1) so that at the end of the study, a final x-ray will be taken in the exact same position. Finally, each participant will receive a dental prophylaxis (D1110) or maintenance (D4910) according to their prior periodontal diagnosis.

Maintenance Visits 2-6 (V2-V6) Participants will return in 3-month intervals at approximately 3, 6, 9, 12, and 15 months (+/- 10 days) for Study Visits V2 - V6. At each of these visits, individuals will be asked about continued participation in the study. Participants will also be asked if there have been any changes to medical or dental history and if they are taking any new medications. Intraoral photographs of the study area will be performed, as well as, collecting measurements from around the dental implant(s), and providing regular dental cleaning. At the 15 month visit, a final x-ray will be taken using the custom x-ray holder made at the first visit.

Clinical and radiographic assessments will include:

  1. BOP: at each of the 4 measured locations surrounding the implant of interest will be recorded as follows:

    1. Score 0 - No BOP
    2. Score 1 - Bleeding dot
    3. Score 2 - Continuous line of blood that fills the sulcus
    4. Score 3 - Profuse bleeding and/or hemorrhage drip.
  2. Probing depths (PD): at 4 locations surrounding the implant of interest (mesiolingual (ML), mesiobuccal (MB), distolingual (DL), and distobuccal (DB)). PD increase must exceed a threshold of 0.8mm to be considered progression.
  3. Recession: measured at each of the 4 locations surrounding the implant of interest.
  4. Keratinized mucosa width: measured at the midbuccal aspect of the implant(s).
  5. Mucosal thickness: assessed with the aid of an endodontic spreader, 2mm below the mucosal margin, at the midbuccal aspect of the implant(s).
  6. Marginal bone loss (MBL): measured by overlaying the baseline and final radiographs and measuring the change in marginal bone levels. Progression will have to exceed a threshold of 0.5mm to be considered.

Study Type

Observational

Enrollment (Estimated)

150

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Carla Sanchez, MS
  • Phone Number: 412-624-1179
  • Email: cab28@pitt.edu

Study Locations

    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15213
        • University of Pittsburgh School of Dental Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

The population from which cases will be recruited are from the patients of record at the University of Pittsburgh Periodontics Department who meet the inclusion criteria of the study.

Description

Inclusion Criteria:

To be enrolled in the study, the participant must meet the following inclusion criteria:

  • adults in good general health (at least ASA 2)
  • having ≥ 1 dental implant that was restored before January 2021
  • patients of the University of Pittsburgh Periodontics Department
  • available for maintenance visits every 3 months for the length of the study

Exclusion Criteria:

  • Active infectious diseases of any kind
  • Pregnant or planning to become pregnant (self-reported)
  • Congenital or metabolic bone disorders
  • Current heavy smokers: Subjects who have smoked more than 1 pack/day within 6 months of study onset
  • Co-morbid conditions that would affect the study outcome or interpretation of study results
  • Require treatment for periodontal disease prior to baseline

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Implants with BOP score 0
Implants with no BOP according to the modified bleeding index at baseline.
With the aid of a periodontal probe, the incidence of BOP, as well as PD, recession and KM will be assessed.
A standardized periapical radiograph of the implant will be completed at the beginning and the end of study to determine the marginal bone loss.
Dental prophylaxis or maintenance will be performed every 3 months.
Implants with BOP score 1
Implants with a bleeding dot at baseline.
With the aid of a periodontal probe, the incidence of BOP, as well as PD, recession and KM will be assessed.
A standardized periapical radiograph of the implant will be completed at the beginning and the end of study to determine the marginal bone loss.
Dental prophylaxis or maintenance will be performed every 3 months.
Implants with BOP score 2
Implants with a continuous line of blood that fills the sulcus at baseline.
With the aid of a periodontal probe, the incidence of BOP, as well as PD, recession and KM will be assessed.
A standardized periapical radiograph of the implant will be completed at the beginning and the end of study to determine the marginal bone loss.
Dental prophylaxis or maintenance will be performed every 3 months.
Implants with BOP score 3
Implants with a profuse bleeding and/or hemorrhage drip at baseline.
With the aid of a periodontal probe, the incidence of BOP, as well as PD, recession and KM will be assessed.
A standardized periapical radiograph of the implant will be completed at the beginning and the end of study to determine the marginal bone loss.
Dental prophylaxis or maintenance will be performed every 3 months.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Marginal Bone Loss (MBL)
Time Frame: Baseline and 15 months
MBL will be calculated by measuring the difference in marginal bone level between the standardized periapical radiographs. Progression will have to exceed a threshold of 0.5mm to be considered.
Baseline and 15 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of BOP
Time Frame: 3, 6, 9, 12 and 15 months

Changes in BOP at each of the 4 sites assessed in baseline, according to Mombelli et al. (1987):

  1. Score 0 - No BOP
  2. Score 1 - Bleeding dot
  3. Score 2 - Continuous line of blood that fills the sulcus
  4. Score 3 - Profuse bleeding and/or hemorrhage drip.
3, 6, 9, 12 and 15 months
Changes in probing depth (PD)
Time Frame: Baseline, 3, 6, 9, 12 and 15 months
Differences in probing depth over the study period. PD increase must exceed a threshold of 0.8mm to be considered progression.
Baseline, 3, 6, 9, 12 and 15 months
Mucosal recession
Time Frame: Baseline, 3, 6, 9, 12 and 15 months
Measured at each of the 4 locations surrounding the implant of interest.
Baseline, 3, 6, 9, 12 and 15 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Peri-implant mucosal phenotype
Time Frame: Baseline and 15 months
Assessed by determining the keratinized mucosa (KM) width, measured in millimeters with a periodontal probe, at the mid-buccal aspect of the implant from the gingival margin to the mucogingival junction and the mucosal thickness, measured in millimeters, at the mid-buccal aspect of the implant, 1.5mm below the gingival margin with an endodontic spreader (0.25mm diameter) and endodontic cursor.
Baseline and 15 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Andrea Ravida, DDS MS, University of Pittsburgh

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 11, 2023

Primary Completion (Estimated)

December 1, 2025

Study Completion (Estimated)

December 1, 2025

Study Registration Dates

First Submitted

September 5, 2023

First Submitted That Met QC Criteria

September 5, 2023

First Posted (Actual)

September 13, 2023

Study Record Updates

Last Update Posted (Actual)

November 2, 2023

Last Update Submitted That Met QC Criteria

November 1, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Peri-Implantitis

Clinical Trials on Clinical measurements

3
Subscribe